A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Bristol-Myers Squibb
Study ID
NCT00743938
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-690514 — DRUG
    Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
  • Erlotinib — DRUG
    Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity

Study Details

The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib

Key Dates

First listed
Aug 29, 2008
Start date
Mar 31, 2009
Status verified
Sep 2015
Primary completion
Aug 31, 2010
Completion
Jun 30, 2012

Study Design

Enrollment
141 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A1
  • Active Comparator: B2

Primary Outcome Measure

To compare the progression-free survival of patients on BMS-690514 with those on erlotinib [ Time Frame: CT/MRI at baseline and every 6 weeks for 36 weeks ]

Locations (9)

FacilityCityStateZIPSite coordinators
Yale University School Of MedicineNew HavenConnecticut06520-
Hematology Oncology, P.C.StamfordConnecticut06902-3628-
Mass General HospitalBostonMassachusetts02114-
Henry Ford HospitalDetroitMichigan48202-2689-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Piedmont Hematology Oncology Associates, PllcWinston-SalemNorth Carolina27103-
Oregon Health & Science UniversityPortlandOregon97239-
Hema/Oncology Assoc. Of NepaDunmorePennsylvania18512-
Cancer Center Of The CarolinasGreenvilleSouth Carolina29605-

Find similar trials in New Haven, CT

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Yale University School Of Medicine· New Haven, CTHematology Oncology, P.C.· Stamford, CTMass General Hospital· Boston, MAHenry Ford Hospital· Detroit, MIMemorial Sloan Kettering Cancer Center· New York, NYPiedmont Hematology Oncology Associates, Pllc· Winston-Salem, NC

Related Studies